Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03154567
Other study ID # SCM-1
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 1, 2017
Est. completion date October 27, 2023

Study information

Verified date April 2024
Source Wayne State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the proposed study to examine the links among stress, craving for marijuana, and marijuana reminders, or "cues". In this study, an agent called yohimbine will be used to produce stress-like responses. Yohimbine is known to cause stress response in studies of alcohol and other substance use disorders. This study intends to show it can be used to cause stress in marijuana users as well.


Description:

Part of this study will be conducted on a residential unit where participants will live for 7 nights over a 2-week period (4 consecutive nights the 1st week and 3 consecutive nights the 2nd week). During that time, participants can't leave the unit unescorted or have visitors. During the inpatient stay participants will participant in experimental sessions where they will be asked to smoke cigarettes containing either marijuana or placebo (a blank). Participants will be asked to take capsules that could contain yohimbine or placebo (blank). Participants will be asked to complete questionnaires and will have their vital signs (blood pressure, heart rate) monitored throughout each session. Participants will be asked to participate in overnight sleep recordings, a polysomnogram (PSG).


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date October 27, 2023
Est. primary completion date October 27, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 55 Years
Eligibility Inclusion Criteria: - Participants (18-55 yr) will be current marijuana users, based on self-report and THC-positive urine samples. - Candidates must meet DSM-5 criteria for Mild-to-Moderate Cannabis Use Disorder (CUD) and be willing to participate in research but not seeking treatment. - Candidates must be in good health, as assessed using data from psychiatric evaluation, extensive substance use history interview, and medical evaluations including medical history, physical exam, standard lab tests and 12-lead ECG. Exclusion Criteria: Candidates with the following conditions will be excluded: - Serious psychiatric illness (e.g. psychotic or bipolar disorder, recent suicide attempts, major depression). - Substance Use Disorders other than Cannabis or Nicotine Use Disorders and Mild Alcohol Use Disorder. - Neurological diseases - Cardiovascular problems (e.g. including systolic BP >140 or <95 mmHg, diastolic BP >90 mmHg, abnormal ECG). - Pulmonary diseases - Systemic diseases - Cognitive impairment (<80 IQ) - Past-month medications that increase study risk. - Women who are pregnant, lactating, or if heterosexually active and not using medically approved birth control. - Candidates seeking Substance Use Disorder treatment. - Individuals unable to give voluntary informed consent will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Yohimbine
Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.

Locations

Country Name City State
United States Tolan Park Medical Building Detroit Michigan

Sponsors (1)

Lead Sponsor Collaborator
Wayne State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Marijuana Craving Visual Analog Scale (VAS) (Self-report measure) Change is being assessed. Marijuana Craving VAS administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1220, 1245, 1300, 1315, 1345.
Primary Marijuana Craving Questionnaire (Self-report measure) Change is being assessed. Marijuana Craving Quest.administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630.
Primary Questionnaire of Smoking Urges (Self-report measure) Change is being assessed. Questionnaire is administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630.
Primary Marijuana Rating Form (Self-report measure) Change is being assessed. Marijuana Rating Form is administered 30 minutes after each smoking episode in the sampling session.
Primary Marijuana Withdrawal Checklist Change is being assessed. Questionnaire is administered every morning and evening.
Primary Subjective Effects Scale Visual Analog Scale (VAS) (Self-report measure) Change is being assessed. Subjective Effects Scale administered at baseline 0900.It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630.
Primary Positive & Negative Affect Schedule (Self-report measure) Change is being assessed. Questionnaire is administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630.
Primary Systolic blood pressure (physiological effects) Change is being assessed. Systolic blood pressure measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630.
Primary Diastolic blood pressure (physiological effects) Change is being assessed. Diastolic blood pressure measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630.
Primary Heart rate (physiological effects) Change is being assessed. Heart rate measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630.
Primary Core-body temperature (physiological effects) Change is being assessed. Core-body temperature measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT00158249 - Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals Phase 2
Completed NCT00842985 - Dronabinol Interactions in Humans N/A
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00227864 - A Brief Marijuana Intervention for Adolescent Women - 1 Phase 3
Completed NCT00227903 - Therapeutic Substance Abuse Treatment in Pregnancy - 1 Phase 2
Completed NCT00218478 - Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1 Phase 1
Completed NCT00249509 - Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals Phase 2
Completed NCT03717272 - Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects Phase 2
Completed NCT00142961 - Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Phase 2
Terminated NCT02102230 - CBT-I for Cannabis Use N/A
Completed NCT00580671 - Treatment for Adolescent Marijuana Abuse N/A
Completed NCT00360269 - Atomoxetine Treatment for ADHD and Marijuana Dependence Phase 2
Completed NCT00227916 - Motivational Interviews for Incarcerated Teens - 1 N/A
Active, not recruiting NCT05322941 - Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) Phase 2
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT01762696 - A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth N/A
Completed NCT03154580 - Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users Phase 1
Completed NCT00217971 - Dronabinol Treatment for Marijuana Addiction Phase 2
Completed NCT00142870 - Effectiveness of Bupropion in Treating Marijuana Dependent Individuals Phase 2